Objective:To evaluate the efficacy and toxicity of gefitinib retreatment of advanced non-small cell lung cancer.Methods:To review the treatment and follow-up data of an advanced non-small cell lung cancer patient who was retreated with gefitinib due to failure of the initial gefitinib therapy and investigate the pertinent liateratures.Results:The initial gefitinib therapy lasted about 8 months,and the patient was retreated with gefitinib after 5 months.The chest CT showed partial remission(PR) 1 month later and then disease progression after 2 months.The overall survival was 21 months.Mild toxicity was observed.Conclusion:Patients with NSCLC may still be expected to achieve prolonged survival through gefitinib retreatment if they initially responded to gefitinib and undergo mild toxicity.%目的:对吉非替尼治疗失败后的晚期NSCLC患者再次使用吉非替尼治疗,分析其疗效及安全性.方法:复习1例吉非替尼治疗失败后的晚期NSCLC患者再次使用吉非替尼治疗及临床资料,结合相关文献探讨其临床特征、治疗及预后.结果:该患者首次使用吉非替尼约8月后耐药,停药5月后再次使用吉非替尼,1月后复查肺部CT提示肺部病灶明显缩小,2个月后再次失效,最终总生存期达21月,使用吉非替尼期间不良反应轻微.结论:曾使用吉非替尼有效的晚期NSCLC患者,再次使用吉非替尼仍有可能延长其生存时间且不良反应轻微.
展开▼
